ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments
ImmunityBio (NASDAQ:IBRX) shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two cancer indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's international reach to 34 countries and is a significant milestone in …